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Abstract 
Background 
Data in the literature suggest the existence of oligometastatic disease, a state in which 
metastases are limited in number and site. Different kinds of local therapies have been used 
for the treatment of limited metastases and in the recent years reports on the use of 
Stereotactic Ablative radiotherapy (SABR) are emerging and the early results on local control 
are promising. 
Patients and methods 
From October 2010 to February 2012, 76 consecutive patients for 118 lung lesions were 
treated. SABR was performed in case of controlled primary tumor, long-term of progression 
disease, exclusion of surgery, and number of metastatic sites ≤ 5. Different kinds of primary 
tumors were treated, the most common were lung and colon-rectal cancer. The total dose 
prescribed varied according to tumor site and maximum diameter. Dose prescription was 48 
Gy in 4 fractions for peripheral lesions, 60 Gy in 8 fractions for central lesions and 60 Gy in 3 
fractions for peripheral lesions with diameter ≤ 2 cm. 
Results 
Dosimetric planning objectives were met for the cohort of patients with in particular V98% = 
98.1 ± 3.4% for the CTV and mean lung dose of 3.7 ± 3.8Gy. Radiological response was 
obtained in the vast majority of patients. The local control at 1, 2 and 3 years was 95%, 89% 
and 89% respectively. No major pulmonary toxicity, chest pain or rib fracture occurred. The 
median follow up was 20 months (range 6–45 months). Overall Survival (OS) at 1, 2 and 3 
years was 84.1%, 73% and 73% respectively. 
Conclusions 
SABR is feasible with limited morbidity and promising results in terms of local contro, 
survival and toxicity. 
Background 
The management for patients with metastatic disease has always been focused on the use of 
systemic therapy alone; this potentially allows to treat microscopic metastatic tumor but 
generally is unable to eradicate gross tumor sites. Local therapies, although effective against 
single lesion tumors, have been used with palliative intent in these settings of patients. In the 
recent years a new evidence emerged about the existence of an intermediate condition 
between localized and widespread systemic disease. In 1995 Hellman and Weichselbaum first 
proposed the idea of an oligometastatic disease [1], in which metastases are limited in 
number and site. They suggested that local treatment through reduction of the tumor burden 
might bring to a better control of disease with consequent lengthening of lifetime. In this 
“scenario” local approaches, surgery or stereotactic ablative radiation therapy, have been 
increasingly utilized mostly for the treatment of lung and liver metastases [2,3]. Although 
surgery is the main modality used [4,5], more recently Stereotactic Body RadioTherapy 
(SBRT) is emerging as an effective alternative for patients unsuitable for surgery. This 
approach enables the delivery of a limited number of ablative doses with highly conformal 
techniques and maximum healthy tissue sparing. Retrospective and prospective reports SBRT 
allowed to achieve excellent local control (LC), more than 90% in some series, to delay 
progression, and to decrease the subsequent need of further chemotherapy treatments [5-9]. In 
this study a set of oligometastatic patients treated with Intensity Modulated Radiation 
Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) in the RapidArc form 
(RA) for lung metastases from different solid tumors was reviewed. The aim of this study 
was to evaluate toxicity, local control and survival. 
Materials and methods 
Patients and procedures 
The present prospective study includes oligometastatic patients with lung metastases from 
different primary tumors. To define the appropriate therapy, each patient was evaluated by a 
multidisciplinary team including a radiation oncologist, a thoracic surgeon and a medical 
oncologist. Patient’s general condition (age, performance status) and disease status 
(histology, other sites of metastases, time to progression) were considered. SBRT was 
performed when the following criteria were met: i) controlled primary tumor, ii) absence of 
progressive disease longer than 6 months, iii) medically inoperable or unresectable, iv) 
number of metastatic sites ≤ 5 (total number in any site). No chemotherapy was given for at 
least 3 months preceding SBRT. The other sites of metastases outside the lung were stable or 
in response to previous treatment, local or systemic. From October 2010 to February 2012, 76 
consecutive patients for 118 lung lesions were treated in our Department. Fifty-four were 
male (70%) and 22 female (30%) with a median age of 68 years (range 38–88 years). 
Different kinds of primary tumors were treated, the most common were lung and colon-rectal 
cancer. Patients characteristics, disease status and treatment features at the time of SBRT are 
shown in Table 1. The median time from the diagnosis to appearance of metastasis was 24 
months (range, 10–144 months) and SBRT was performed at a median-time of 48 months 
(range, 10–180 months) after diagnosis of metastases. 
  
Table 1 Patients characteristics, disease status and treatment features 
Characteristic n. % 
No. of patients 76  
     Male 54 70 
     Female 22 30 
                     68 -  
Range, years 38-88 - 
Primary Tumor   
     Colorectal 29 38 
     NSCLC 18 24 
     Sarcoma 6 8 
     Genitourinary 8 10.5 
     Other 15 19.5 
Other Metastatic sites   
     Bone 2 2.6 
     Visceral 4 5.2 
Time since diagnosis (mos)   
     Median 48 - 
     Range 10-180 - 
Treatment No. % 
Lung lesions treated 118  
No. of lung lesions (per patient)   
 49 64 
 18 24 
 9 12 
Dose prescription (per lesion)   
     48 Gy/12 Gy fraction 95 80.5 
     60 Gy/20 Gy fraction 7 6 
     60 Gy/7.5 Gy fraction 16 13.5 
Treatment 
The total dose of SBRT prescribed varied according to the tumor site (central or peripheral) 
and maximum diameter of the lesions. For peripheral lesions up to 2 cm the dose prescription 
was 60 Gy in 3 consecutive fractions, for peripheral lesions between 2 and 3 cm it was 48 Gy 
in 4 consecutive fractions while for central lesions was 60 Gy in 8 consecutive fractions. All 
patients were planned and treated in supine position with arms crossed above their head. A 
thermoplastic mask was used to immobilize the thoracic and abdominal regions and reduce 
the residual body motion. A 4D-CT scan going from the mandible to the third lumbar 
vertebra was acquired for all patients for planning purposes. The Gross Tumor Volume 
(GTV) consisted of radiological lesion identified in lung parenchyma window and was 
delineated in each 4D-CT phase; the Clinical target volume (CTV) was defined as coincident 
to the GTV. The Internal Target Volume (ITV) was defined as the envelope of the CTVs 
from each respiratory phase. The final PTV was defined as the ITV plus an isotropic margin 
of 5 mm. Organs at risk (OARs) considered were: lungs, heart, spinal cord, oesophagus and 
chest wall. The plan objective was to cover at least 98% of the CTV (ITV) volume with 98% 
of the prescribed dose (V98% = 98%) and for the PTV to cover 95% of the volume with 95% 
of the dose (V95% = 95%). Constraints for OARs were D1% < 20Gy on spinal cord, D1% < 
30Gy for heart and oesophagus. For ipsi- contra- and joint lungs excluding PTV, constraints 
of V5Gy < 30%, V10Gy < 20%, V20Gy < 10% were set and a mean lung dose <4Gy was 
imposed. All RA plans were designed and optimised with RA technique (Version 8.9-10.28, 
Varian, Palo Alto, CA, USA) using two partial and coplanar arcs of ≈ 200°; single isocentre 
was used in most of the cases. Jaw tracking was used to best reduce the leaf residual 
transmission. The final dose distributions were computed with the Analytical Anisotropic 
Algorithm (AAA) implemented in the Eclipse planning system. Patients were treated with 
10MV flattening filter free (FFF) beams using the TrueBeam linac (Varian, Palo Alto, CA, 
USA) equipped with the millennium MLC with leaf dimension at isocenter of 5 mm. A 
maximum dose rate of 2400 MU/min was used. Before each fraction image guided RT was 
performed by means of kV cone beam CT (CBCT) aligning to the tumor in the reference 
planning CT. 
Outcome evaluation 
Clinical outcome was evaluated by thoracic and abdominal CT scan and 18FDG-PET-CT 
before treatment, CT scan every 3 months and/or 18FDG-PET-CT if needed after treatment. 
Complete Remission (CR) was defined as the disappearance of the lesions at CT scan; a 
reduction greater than 30% was considered Partial Remission (PR); any growing lesion not 
clearly ascribable to fibrosis was reported as Progression of Disease (PD). The incidence of 
toxicity was graded according to the NCI CTCAE vs 3.0 scale every 3 months as well. 
Statistical analysis 
Data are reported as number and percentage or mean and SD where appropriate. Survival 
curves were generated using the Kaplan-Meier method. Overall survival times were 
calculated starting from the treatment beginning. All analyses were performed with Stata 10 
(StataCorp, College Station, TX). 
Results 
In Figure 1, an example of dose distribution in one of our patients is shown, providing a 
qualitative overview of the target coverage and dose fall off outside the PTV. Similar results 
were obtained for the other patients. 
Figure 1 An example of dose distribution for a 3-lesion patient. The 50% isodose 
distribution is pointed out showing a qualitative overview of the target coverage and dose fall 
down outside the PTV. 
A total of 118 lesions were treated in 76 patients. In 27/76 patients (36%) more than one lung 
metastases was irradiated. Dose prescription varied according to lesions site, peripheral or 
central, and volume: 48 Gy/12Gy fraction in 95 lesions (80.5%); 60 Gy/7.5Gy fraction in 16 
lesions (13.5%), and 60Gy/20Gy fraction in 7 lesions (6%) as shown in Table 1. All patients 
completed the planned treatment. The 6 patients in the cohort who were affected by 
synchronous metastases in the lung and in other sites, were treated only for the lung lesions 
because the disease in the other sites (bones and viscera) was stable and/or asymptomatic. 
Dosimetric data 
Figure 1 presents an example of dose distributions in axial, coronal and sagittal views for one 
patient for one of the most complex patients with two isocentres. Color wash for dose scaling 
was set in the range 50-105%. Figure 2 shows the average cumulative dose volume 
histograms (DVH) computed for the whole cohort of patients (solid lines). The dashed lines 
represent the inter-patient variability expressed at + −1 standard deviation. For CTV and 
PTV, given the different prescriptions, dose is expressed in percentage. For Organs At risk in 
Gy. Table 2 summarised the numerical analysis performed on CTV, PTV and OARs and 
based on DVHs. Reported are the main parameters valuable for plan assessment, the 
corresponding planning objectives, the mean values of the findings (with 1 standard deviation 
uncertainty) and the observed range. As it can be derived from the table, all objectives were 
on average met. 
Figure 2 Average dose volume histograms for CTV, PTV and organs at risk. Dashed 
lines represent inter-patient variability at + −1 standard deviation. 
Table 2 Summary of the DVH analysis for the CTV, PTV and Organs at Risk 
Parameter Objective Mean ± SD Range 
CTV 
Volume = 13.9 ± 25.8 cm3 Range = [.5 – 183.6] cm3 
Mean [Gy] 100% 101.4 ± 1.7 [98.4 - 106.4] 
V98% [%] >98% 98.1 ± 3.4 [80.3 – 100.0] 
D99% [Gy] Maximize 98.25 ± 1.7 [94.3 - 103.2] 
D1% [Gy] Minimize 104.3 ± 2.1 [99.8 - 112.9] 
PTV 
Volume = 42.3 ± 51.2 cm3 Range = [2.5 – 333.1] cm3 
Mean [Gy] 100% 100.3 ± 0.3 [96.8 - 104.9] 
V95% [%) >95% 96.7 ± 1.9 [90.2 - 99.9] 
D99% [Gy] Maximize 93.1 ± 2.0 [89.5 - 96.6] 
D1% [Gy] Minimize 104.8 ± 1.8 [101.9 - 112.9] 
Lungs 
Mean [Gy] <4Gy 3.7 ± 3.8 [0.5-16.8] 
V5Gy [%] <30% 17.9 ± 18.8 [0.1-78.2] 
V10Gy [%] <20% 11.2 ± 14.2 [0.1-65.8] 
V20Gy [%] <10% 5.2 ± 7.4 [0.0-34.6] 
Spinal Cord 
D1% [Gy] <20Gy 10.2 ± 5.6 [2.2 - 21.7] 
Heart 
D1% [Gy] <30Gy 11.3 ± 10.9 [0.5 - 28.6] 
Esophagus 
D1% [Gy] <30Gy 16.3 ± 11.5 [5.1 – 36.1] 
Dx%: dose received by at least x% of the volume; Vx%: volume receiving at least x% of the dose. 
Data are reported as average values plus or minus standard deviation and range. 
Local control 
A radiological response was obtained in all lesions after treatment. At the last observation, 
Complete Remission (CR) was recorded in 71/118 cases (60%) Partial Remission (PR) in 
33/118 (28.5%), Stable disease (SD) in 4/118 (3%) and in-field-progression in 10/118 (8.5%). 
About in field progression it was exclusively local in 5 cases (3 patients) and occurred at 6, 
12 and 18 months after treatment; patients underwent to new line of chemotherapy and are 
alive at 21, 22 and 23 months. In the other 5 cases (4 patients) it was associated with distant 
tumor progression and 3/ 4 patients died within a year from the progression. The 1, 2 and 3 
years Local Control Rate was 95%, 89% and 89% respectively as shown in Figure 3a. 
Depending on the primary tumor, recurrence appeared in 3 of 29 patients with colorectal 
tumor (locally and distance), and in 4 of 15 patients with other histology (2 locally and 
distance). No correlation between delivered doses and local control was present. The median 
time between SBRT and progression (and therefore new chemotherapy treatment) was 10 
months (range: 3–19 months). 
Figure 3 a) Local control; b) Overall survival (OS) and Disease Specific Survival (DSS). 
Figure a refers to the 118 treated lesions while b to the 76 patients. 
Toxicity 
No acute toxicity occurred. At the last examination 80% of patients presented a late G1 lung 
toxicity (mostly radiological fibrosis in <25% of lung volume. No severe (G2-G4) pulmonary 
toxicity, chest pain or rib fracture was observed until last examination. 
Survival 
The median follow up was 18 months (range 6–45 months). At the time of analysis 58 
patients (76%) are alive and 18 (24%) patients are dead; 2 patients died early for causes 
unrelated to disease progression or treatment toxicity. The median survival was 20 months 
(range 6–45 months). OS at 1, 2 and 3 years was 84% , 73% and 73% respectively; Disease 
Specific Survival (DSS) at 1,2 and 3 years was 85%, 75% and 75% respectively (Figure 3b). 
Progression free survival (PFS) at 1,2 and 3 years was 83%, 70% and 70% respectively. In 
univariate analisis, no correlation was found between survival and sex, age, presence and site 
of other sites of metastases, volume of lung lesions or total dose of SBRT delivered. Neither 
the histology of primary tumor, affected survival: 2-year OS in patients with lung metastases 
from Colorectal tumor , NSCLC and Genitourinary tract was 78% , 77% and 75% 
respectively. Only in patients with sarcoma the 2 years OS was 100% but the number of 
patients is very low (6 patients). 
Discussion 
The treatment for metastatic patients mainly consisted in the use of chemotherapeutic agents; 
the median survival and the treatment choice depend on several prognostic factors: patients 
age, PS, primary histology, site and number of metastases. The role of radiation therapy in 
the management of metastatic disease has been principally limited to palliation but we now 
have an opportunity to challenge this statement. Probably there is an intermediate state 
defined by a long latent interval between the treatment of the primary tumour and the 
appearance of metastases. Hellman and Weichselbaum [1] first proposed the idea of an 
oligometastatic state in 1995. They suggested that for many cancers a few metastases exist at 
first, before the malignant cells acquire widespread metastatic potential. Theoretically, if 
ablative hypofractionated radiation therapy could be delivered during the oligometastatic 
phase, this might modify disease outcome in patients in which up to now radiotherapy was 
used only with a palliative intent. The role of SBRT for the treatment of oligometastases was 
investigated also in other sites, often localized in not-accessible sites, Casamassima [10] 
investigated SBRT in adrenal gland metastases showing in a retrospective analysis on 48 
patients an actuarial local control as great as 90%. Bonomo [11] investigated the role of 
SBRT in paracardiac metastases (on 16 patients) and demonstrated a crude local control of 
75% in this challenging localisation. Experimental data from multiple cancer models have 
provided sufficient evidence to propose a paradigm shift, since some of the effects of ionizing 
radiation are recognized to give a contribution to systemic antitumor immunity. Recent 
examples of objective responses achieved by adding radiotherapy to immunotherapy in 
metastatic cancer patients support this view. Therefore, the traditional palliative role of 
radiotherapy in metastatic disease is evolving into that of a powerful adjuvant for 
immunotherapy [12]. Innovative techniques have revolutionized radiation oncology within 
the last decade. Using IMRT or VMAT the conformity of the dose to the tumor is increased 
while sparing of healthy tissue is optimized. More recently, in our experience, RA with FFF 
beams permits a best treatment. In our series oligometastatic patients with lung metastases 
from different kind of solid tumors underwent SBRT with RA. Using this approach good 
results were obtained in terms of local response in most patients, local control rate at 1, 2 and 
3 years was 95%, 89% and 89% respectively. These results are comparable with other studies 
in literature. In Table 3 selected trials of stereotactic body radiation therapy for lung 
metastases are shown [13-18]. Le [14] reported the results of a phase II trial using SBRT with 
a dose of 50Gy in 10 fractions in the treatment of oligometastatic disease resulting in a 2-year 
local control rate for all treated lesions of 67%. Several recent reports recorded high rate of 
OS using SBRT in oligometastatic patients. Norihisa [15] treated 35 patients with one or two 
lung metastases. The primary site was controlled and there were no other organs involved. 
The original dose of 48Gy in four fractions was escalated to 60Gy in five fractions for 16 
patients. Two-year results for overall survival, local control and progression-free survival 
were 84%, 90% and 35%, respectively. Again, Salama [16] treated 61 patients with 113 
metastases performing a dose escalation increasing from 24Gy in 3 fractions to 48Gy in 3 
fractions. One and 2 year progression free survival were 33.3% and 22%, 1-year and 2-year 
overall survival were 81.5% and 56.7%. Finally, Rusthoven [17] reported a phase I/II 
prospective study of SBRT for metastatic lung tumors. Thirty-eight patients with 63 lesions 
were treated and achieved a 2-year local control rate of 96%, but a 2-year overall survival of 
only 39%. Also in terms of OS at 1 and 2 years our results are comparable with these series 
with values of 85% and 66% respectively. Despite the heterogeneous characteristics of 
oligometastatic patients present both in our data and in other published studies, these findings 
indicate that the use of SBRT gives an advantage in terms of local control, disease free 
survival and overall survival to a significant percentage of patients: generally ~ 20% of 
patients remain disease-free 2–4 years after SBRT [13-23]. Generally SBRT presents 
negligible toxicity: the ratio of patients with grade 3 acute or late adverse event is less than 
10%; in our series no grade 3 or late toxicity was recorded. Different prognostic factors were 
analysed, in particular age, sex, primary tumor histology, disease free interval, metastases 
site, size and number and dose prescription. As shown in several series the following factors 
significantly affect local control, PFS and OS: some histology of primary tumor (i.e. breast 
cancer) [24], disease-free interval of more than 12 months [25,26], target position [17,27-29], 
number (≤3) [16,30-32] and size of metastases (smaller than 3 cm) [17,20,21,33-35], and 
total delivered dose with biological equivalent dose (BED) larger than 100 Gy10 [24-37]. In 
our experience, however, no factors statistically affected outcome of patients. This finding is 
probably related to the characteristics of our series: most patients had unfavourable histology 
(mostly GI tumor and NSCLC), all had primary tumor controlled with disease free interval 
greater than 12 months. 
  
Table 3 Summary of selected trials of Stereotactic Body Radiation Therapy for lung 
metastases 
Study No 
patients 
Median dose/ 
no fractions 
Median FU 
mos (range) 
Local 
control 
rate 
Overall 
Survival 
Toxicity 
Okunieff et al 
[13] 
50 50 Gy/10 18.7 (3.7-60.9) 3-yr 91% 2-yr 50% G2 6.1% 
48 Gy/6 G3 2% 
57 Gy/3  
Norihisa et al 
[15] 
34 48 Gy/4 27 (10-80) 2-yr 90% 2-yr 84% G2 12% 
60 Gy/5 G3 3% 
Le et al [14] 32 15 Gy/1 - 1-yr 54%  G2-G3 4 
20 Gy/1 1-yr 54% G5 3 
25 Gy/1 1-yr 91% Dose ≥ 25 
Gy 
30 Gy/1 1-yr 91%  
 2-yr 67%  
Salama et al 
[16] 
61 24 Gy/3 20.9 (3-60.5) 1-yr 67.2% 2-yr 56.7% G3 3 
48 Gy/3 2-yr 52.7%  
Rushoven et 
al [17] 
38 60 Gy/3 15.4 (6-48) 2-yr 96% 2-yr 39% G3 3 (8%) 
Ricardi et al 
[18] 
61 45 Gy/3 20.4 (3-77) 2-yr 89% 2-yr 66.5% G3 1 
(1.6%) 26 Gy/1 
Conclusion 
We have shown that, in oligometastatic patients with lung metastases, SBRT is feasible with 
limited morbidity. The clinical results obtained are highly satisfactory. Well-designed 
collaborative trials, including stratification of patients by histology, are necessary to draw 
final conclusions, in a multidisciplinary perspective, in this field and to determine whether 
SABR, with it’s lower morbidity, could be a real alternative to surgery in the treatment of 
oligometastatic patients. 
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